Welcome to our dedicated page for Argenx Se news (Ticker: ARGX), a resource for investors and traders seeking the latest updates and insights on Argenx Se stock.
argenx SE (ARGX) is a global immunology company listed on Euronext and Nasdaq that focuses on severe autoimmune diseases through antibody-based medicines. Its news flow centers on clinical data, regulatory milestones, commercial performance and strategic updates related to its FcRn-targeting medicine VYVGART and a broader pipeline of experimental antibodies.
Investors and healthcare observers following ARGX news can read about regulatory interactions such as the U.S. Food and Drug Administration’s acceptance for priority review of a supplemental Biologics License Application (sBLA) for VYVGART in acetylcholine receptor antibody seronegative generalized myasthenia gravis (gMG). Company announcements also cover Phase 3 trial readouts, including the ADAPT SERON study in seronegative gMG and other registrational programs across neuromuscular and autoimmune indications.
argenx regularly reports preliminary and quarterly financial results, highlighting global product net sales from the VYVGART franchise and outlining strategic priorities tied to its long-term "Vision 2030". News items describe the expansion of VYVGART and VYVGART Hytrulo across gMG, chronic inflammatory demyelinating polyneuropathy (CIDP) and immune thrombocytopenia (ITP) in certain regions, as well as progress with pipeline candidates such as empasiprubart and ARGX-119.
Corporate news includes leadership transitions, conference presentations at major medical and investor meetings, and updates from the company’s Immunology Innovation Program (IIP). For readers interested in ARGX stock and the evolution of its immunology franchise, this news feed provides a consolidated view of clinical, regulatory, commercial and corporate developments as disclosed in argenx press releases and related filings.
argenx SE announced the closing of its global offering of 3,593,750 ordinary shares, generating gross proceeds of approximately $1.15 billion. This includes the full exercise of underwriters' options for 468,750 ADSs. The shares will commence trading on Euronext Brussels. The offering was led by J.P. Morgan, Morgan Stanley, BofA Securities, and Cowen. This press release serves informational purposes and does not constitute an offer to sell or solicitation.
argenx SE announced the full exercise of an option by underwriters for its global offering, resulting in the sale of an additional 468,750 American Depositary Shares (ADSs). This action brings the total gross proceeds from the offering to approximately $1.15 billion (~€954.8 million), with a total of 3,593,750 ordinary shares sold. The closing of this offering is expected on February 5, 2021, subject to customary conditions. The offering is conducted under an automatically effective shelf registration with the SEC.
argenx SE announced a global offering of ordinary shares and American Depository Shares (ADSs), priced to raise approximately $1.0 billion (about €830.3 million). It involves the sale of 1,608,000 ADSs at $320.00 each and 1,517,000 ordinary shares at €265.69 each, with expected closing on February 5, 2021. The offering includes a 30-day option for underwriters to purchase an additional 468,750 shares. The securities are offered under a shelf registration statement filed with the SEC.
argenx SE announced a global offering of $750 million (approx. €618 million) of ordinary shares, represented by American Depository Shares (ADSs). This offering includes a U.S. offering and a European private placement, expected to close simultaneously. Notably, Baillie Gifford has shown interest to purchase up to $415 million (approx. €342 million) in shares. The offering allows underwriters a 30-day option to buy an additional 15% of shares. argenx's ADSs trade on Nasdaq under ARGX, while ordinary shares are listed on Euronext Brussels.
argenx announced the continuation of patient enrollment in the ADHERE trial for efgartigimod in treating chronic inflammatory demyelinating polyneuropathy (CIDP). The independent data monitoring committee confirmed this decision after interim efficacy and safety assessments surpassed predefined thresholds. The aim is to enroll approximately 130 patients to support the drug's potential registration. The company underscores the clinical proof-of-concept for efgartigimod in CIDP, enhancing its portfolio of treatments for autoimmune diseases.
On November 17, 2020, argenx (ARGX) launched a docuseries titled A Mystery to Me, focusing on Myasthenia Gravis (MG), a rare autoimmune disease. The series aims to raise awareness of MG by showcasing the lives of three individuals affected by it. The docuseries is produced by Sarofsky Productions and will be available on MG-United.com following its debut. CEO Tim Van Hauwermeiren emphasized the importance of listening to MG patients to better understand their challenges. The MG Foundation highlighted the connection this series could foster within the community, particularly during the COVID-19 pandemic.
argenx (Euronext & Nasdaq: ARGX), a global immunology company, will host a conference call on October 22, 2020, at 2:30 p.m. CET (8:30 a.m. ET) to discuss its Q3 2020 financial results and provide a business update. The live call can be accessed via the Investors section of their website, with a replay available for one year. argenx focuses on severe autoimmune diseases and cancer treatments, evaluating efgartigimod and cusatuzumab in collaboration with Janssen. The company aims to translate immunology breakthroughs into innovative antibody-based medicines.
argenx, a global immunology company, announced new partnerships with Chugai and the Clayton Foundation to enhance its antibody engineering capabilities. This expansion includes access to advanced technologies for developing first-in-class medicines targeting severe autoimmune diseases and cancers. Additionally, argenx is extending its collaboration with Halozyme, securing subcutaneous delivery options for three more product candidates. These strategies aim to strengthen argenx's innovative pipeline and solidify its leadership in immunology.
On October 5, 2020, argenx (ARGX) announced new findings from its Phase 3 ADAPT trial for efgartigimod, a treatment for generalized myasthenia gravis (gMG). The results, presented at the MGFA 2020 Virtual Scientific Session, demonstrated significant improvements in patients' daily functioning and safety comparable to placebo. Notably, over 55% of treated patients showed substantial improvements in key scoring metrics. The company plans to submit a Biologics License Application to the FDA by the end of 2020, aiming for commercialization in 2021.
On September 2, 2020, argenx (Euronext & Nasdaq: ARGX) announced participation in key healthcare conferences. Management will conduct a fireside chat at the Baird Global Healthcare Conference on September 9 at 12:15 p.m. ET, followed by the Morgan Stanley Global Healthcare Conference on September 14 at 1:30 p.m. ET and BofA Global Healthcare Conference on September 17 at 10:50 a.m. BST. Lastly, a panel will take place at the Stifel Immunology & Inflammation Summit on October 1 at 11:00 a.m. ET. More details are available on the company’s website.